AZD-9773 (BTG)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameAZD-9773 (BTG)
Drug Alias NameCytoFabCytoTAb
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsSepsis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBtg Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsSepsis

Other Information

ATC CodeN/A
Related LinksN/A